Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

医学 射血分数 达帕格列嗪 心力衰竭 内科学 血压 射血分数保留的心力衰竭 心脏病学 人口 安慰剂 糖尿病 2型糖尿病 内分泌学 环境卫生 病理 替代医学
作者
John W. Ostrominski,Muthiah Vaduganathan,Senthil Selvaraj,Brian Claggett,Zi Michael Miao,Akshay S Desai,Pardeep S. Jhund,Mikhail Kosiborod,Carolyn S.P. Lam,Silvio E. Inzucchi,Felipe Martínez,Rudolf A. de Boer,Adrian F. Hernandez,Sanjiv J. Shah,Magnus Petersson,Anna Maria Langkilde,John J.V. McMurray,Scott D. Solomon
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:148 (24): 1945-1957 被引量:2
标识
DOI:10.1161/circulationaha.123.065254
摘要

Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population. In this post hoc analysis of the DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure), we evaluated clinical profiles and treatment effects of dapagliflozin among participants with aTRH.DELIVER participants were categorized on the basis of baseline blood pressure (BP), with aTRH defined as BP ≥140/90 mm Hg (≥130/80 mm Hg if diabetes) despite treatment with 3 antihypertensive drugs including a diuretic. Nonresistant hypertension was defined as BP above threshold but not meeting aTRH criteria. Controlled BP was defined as BP under threshold. Incidence of the primary outcome (cardiovascular death or worsening heart failure event), key secondary outcomes, and safety events was assessed by baseline BP category.Among 6263 DELIVER participants, 3766 (60.1%) had controlled BP, 1779 (28.4%) had nonresistant hypertension, and 718 (11.5%) had aTRH at baseline. Participants with aTRH had more cardiometabolic comorbidities and tended to have higher left ventricular ejection fraction and worse kidney function. Rates of the primary outcome were 8.7 per 100 patient-years in those with controlled BP, 8.5 per 100 patient-years in the nonresistant hypertension group, and 9.5 per 100 patient-years in the aTRH group. Relative treatment benefits of dapagliflozin versus placebo on the primary outcome were consistent across BP categories (Pinteraction=0.114). Participants with aTRH exhibited the greatest absolute reduction in the rate of primary events with dapagliflozin (4.1 per 100 patient-years) compared with nonresistant hypertension (2.7 per 100 patient-years) and controlled BP (0.8 per 100 patient-years). Irrespective of assigned treatment, participants with aTRH experienced a higher rate of reported vascular events, including myocardial infarction and stroke, over study follow-up. Dapagliflozin modestly reduced systolic BP (by ≈1 to 3 mm Hg) without increasing risk of hypotension, hypovolemia, or other serious adverse events, irrespective of BP category, but did not improve the proportion of participants with aTRH attaining goal BP over time.aTRH was identified in >1 in 10 patients with heart failure and left ventricular ejection fraction >40% in DELIVER. Dapagliflozin consistently improved clinical outcomes and was well-tolerated, including among those with aTRH.URL: https://www.clinicaltrials.gov; Unique identifier: NCT03619213.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阿绿发布了新的文献求助10
4秒前
5秒前
5秒前
雨柏完成签到 ,获得积分10
5秒前
wanci应助qwe1108采纳,获得10
6秒前
明天过后完成签到,获得积分10
8秒前
jin完成签到,获得积分10
9秒前
yhy完成签到 ,获得积分10
10秒前
黑色卡布奇诺完成签到,获得积分20
10秒前
tanglu发布了新的文献求助10
10秒前
可爱的函函应助梁大海采纳,获得10
10秒前
成就绮琴完成签到 ,获得积分10
11秒前
xicifish完成签到,获得积分10
11秒前
目光之澄完成签到,获得积分10
12秒前
wanci应助研友_ndDPBn采纳,获得10
12秒前
耍酷的白梦完成签到,获得积分10
13秒前
miracle完成签到 ,获得积分10
14秒前
coding完成签到,获得积分10
15秒前
16秒前
犹豫水蓝完成签到,获得积分10
17秒前
yin完成签到,获得积分10
17秒前
JUGG完成签到,获得积分10
17秒前
CipherSage应助阿湫采纳,获得10
18秒前
FIN应助手机采纳,获得20
18秒前
星辰大海应助东黎采纳,获得10
18秒前
量子星尘发布了新的文献求助10
18秒前
wujingshuai完成签到,获得积分10
19秒前
少年完成签到,获得积分10
19秒前
星辰大海应助ficus_min采纳,获得10
20秒前
小柒柒完成签到,获得积分10
21秒前
sdfwsdfsd完成签到,获得积分10
22秒前
亮仔完成签到,获得积分10
23秒前
土豆丝发布了新的文献求助10
23秒前
ylw完成签到,获得积分20
24秒前
西门明雪完成签到,获得积分10
24秒前
24秒前
烟花应助万松辉采纳,获得10
25秒前
爆米花应助不站在雾里采纳,获得10
25秒前
yy完成签到,获得积分20
26秒前
高贵宛海完成签到,获得积分10
26秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048